Clinical Trials
The Harold Schnitzer Diabetes Research Center is committed to promoting and conducting cutting-edge clinical research. Our goal is to enhance the quality of life of those living with or affected by diabetes
Our efforts to find a cure for diabetes, and to improve life for people with this condition, are made possible by volunteers who participate in research studies. When you volunteer, you help us answer important questions about diabetes.
Below is a list of current research at the Harold Schnitzer Diabetes Research Center. If you are interested in participating, call our research coordinators at 503 494-4704.
Current Clinical Research Studies at the Harold Schnitzer Diabetes Health Center
If you would like to be considered to participate in any of our research studies please call 503 494-4704, or complete our Online Application Form.
Type 1 Diabetes Research Opportunity
Study started on:
Currently recruiting patients for this study?Yes
Principal Investigator is Andrew Ahmann, MD
The OHSU Harold Schnitzer Diabetes Health Center Research Department is conducting a 20-week research study to compare the effectiveness, safety and tolerability of a new, more concentrated form of insulin glargine (U300) with that of the currently marketed insulin glargine U100, also known as Lantus® in patients with type 1 diabetes mellitus.
- You may qualify if you:
- Are 18 to 70 years of age
- Have been diagnosed with type 1 diabetes for at least 1 year
- Currently take multiple daily insulin injections (not on premixed insulin and have not used an insulin pump for at least 6 months)
- Are not on any additional oral or injected anti-diabetes medications
- Have an HbA1c less than 9%
All study-related care is provided at no cost to qualified participants including physical examinations, a glucose meter and supplies, study drugs and supplies, and laboratory tests. Compensation of up to $730 will be provided.
Contact the OHSU Harold Schnitzer Diabetes Health Center Research Department at (503) 494-4704 or by email at DMResearchCenter@ohsu.edu for more information.
eIRB #8463
FLAT Sugar Study
Study started on:
Currently recruiting patients for this study? Yes
Principal Investigator is Andrew Ahmann, MD
Early studies suggest that when people take long-acting insulin and metformin, they have fewer blood sugar extremes when they also take a new type of medicine called glucagon-like polypeptide-1 (GLP-1) agonist named exenatide, instead of meal-time insulin. Participants are asked to take part in an eight month study to find out if middle-aged and older people with Type 2 diabetes who have added risk factors for heart disease have fewer blood sugar extremes when they take exenatide, instead of meal-time insulin, in addition to long-acting insulin and metformin.
You may qualify if you:
Are 40 to 75 years of age with a history of cardiovascular disease, or 55-75 with risk factors for cardiovascular disease
- Have been diagnosed with type 2 diabetes for at least 12 months
- Currently take insulin (if on a pump, must be willing to use injections during the study)
- Are able to tolerate metformin
- Have a BMI less than 40 kg/m2
- Have an HbA1c between 7.5-8.5%
All study-related care is provided at no cost to qualified participants including physical examinations, a glucose meter and supplies, study drugs, and laboratory tests. Compensation of up to $320 will be provided.
Contact the OHSU Harold Schnitzer Diabetes Health Center Research Department at (503) 494-4704 or by email at DMResearchCenter@ohsu.edu for more information.
eIRB #8463
T1D Exchange Study
Study started on: 8/23/10
Currently recruiting patients for this study? No
Principal Investigator is Andrew Ahmann, MD
Currently, large gaps exist in our knowledge and understanding of the best way to manage type 1 diabetes in children and adults. The overall objective of this study is to improve the care of people with type 1 diabetes through sharing data in a common data repository. This study aims to collect core clinical and laboratory data on persons with type 1 diabetes in order to address important clinical issues, develop new research protocols, and locate participants for future clinical studies.
TrialNet Study
TrialNet Natural History Study of the Development of Type 1 Diabetes and Oral Insulin Study
Study started on: 2/13/2009
Currently recruiting patients for this study? Yes
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals. At risk individuals are those that have a blood relative with type 1 diabetes. Close relatives of people with type 1 diabetes are being studied in three steps (phases): Screening, Baseline Risk Assessment, and Follow-Up Risk Assessments.
ITN018A Study
A Phase I Trial of Proleukin® and Rapamune® in Recent-onset Type 1 Diabetes Mellitus
Study started on: 5/15/2009
Currently recruiting patients for this study? No
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to look at the safety of using two separate drugs (Proleukin and Rapamune) in combination in people with recent-onset type 1 diabetes. These two drugs have never been used together in humans and have not been used by people with diabetes.
LAR 105 Study
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
Study started on: 6/2/2006
Currently recruiting patients for this study? No
Principal Investigator is Andrew Ahmann, MD
The purpose of this study is to look at the safety, tolerability, and effectiveness of an investigational (experimental) injectable drug (exenatide LAR) in people with type 2 diabetes.
